<- Go Home
Lundbeck Research USA, Inc.
Lundbeck Research USA, Inc. researches and develops drugs for the treatment of various psychiatric and neurological disorders. The company develops drugs for the treatment of Alzheimer’s disease, depression, Parkinson’s disease, and schizophrenia. Lundbeck Research USA, Inc. has strategic alliances with Takeda Pharmaceutical Co., Limited and Otsuka Pharmaceutical Co., Ltd. Lundbeck Research USA, Inc. was formerly known as Synaptic Pharmaceutical Corporation and changed its name to Lundbeck Research USA, Inc. in February 2005. The company was founded in 1987 and is based in Deerfield, Illinois. As of March 6, 2003, Lundbeck Research USA, Inc. operates as a subsidiary of H. Lundbeck A/S.
Market Cap
$71.3M
Volume
15.0K
Cash and Equivalents
$26.2M
EBITDA
-$29.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$3.0M
Profit Margin
100.00%
52 Week High
$6.89
52 Week Low
$3.65
Dividend
N/A
Price / Book Value
-7.37
Price / Earnings
-2.43
Price / Tangible Book Value
-7.37
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$30.3M
Return on Equity
67.93%
Return on Assets
-38.98
Cash and Short Term Investments
$27.8M
Debt
N/A
Equity
$28.4M
Revenue
$3.0M
Unlevered FCF
-$21.1M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium